Recently, new immune checkpoint therapies (ICTs) represented by PD-1/PD-L1 and CTLA-4 inhibitors have been demonstrated in clinical trials as treatments for ccRCC (Motzer et al., 2019). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.